Turning To Not-For-Profits, AstraZeneca Bolsters Early Stage R&D
Executive Summary
With patent expirations of major drugs looming, pharmaceutical companies are looking to trim expenses, especially in R&D, where expansive budgets have not generated returns – at least in terms of marketable products.
You may also be interested in...
Deals Of The Week: J&J/Crucell, Merck/Beijing Genomics Institute …
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
Deals Of The Week: J&J/Crucell, Merck/Beijing Genomics Institute …
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts
In a bid to protect its most valuable product, Lantus, Sanofi’s new diabetes division intends to provide holistic solutions in an effort to help patients better manage their disease. Will it work?